Inter Parfums buy
This article was originally published in The Rose Sheet
Executive Summary
Sales from acquired Tristar mass market fragrance brands could reach $15 mil. within 12 months, fragrance marketer says. Inter Parfums' wholly-owned subsidiary, Jean Philippe Fragrances, received approval from San Antonio, Texas bankruptcy court to buy certain Tristar trademarks and intellectual property for $3.5 mil. and inventory for $4.7 mil., firm announces May 1. Tristar's fragrance portfolio includes Royal, Royal Crown II, Regal and Club Exclusive. Formal purchase agreement to be signed shortly; deal is expected to close by June 1. Fragrance Impressions, a newly formed company owned by Tristar management, will purchase remaining assets of Tristar. Jean Philippe announced its bid in March following Tristar's Chapter 11 filing (1"The Rose Sheet" March 18, 2002, p. 3)...
You may also be interested in...
Inter Parfums
Purchase of Tristar fragrances may provide opportunity to expand distribution of mass market brands into Wal-Mart, CEO Jean Madar says during Q1 sales and earnings release May 14. Firm's wholly-owned subsidiary recently received approval of purchase from San Antonio Bankruptcy Court and expects to close definitive agreement by end of the month (1"The Rose Sheet" May 6, 2002, In Brief). Inter Parfums mass market sales increased 9% on strong performances by Aziza and Intimate health and beauty aids, while prestige fragrances were down 10% in constant dollars, reflecting fewer launches compared with same period last year. Net sales declined 8.5% to $28.4 mil. and net income fell 1% to $2 mil...
Inter Parfums Seeking To Acquire Tristar Fragrance Portfolio For $10 Mil.
Inter Parfums has signed a letter of intent with fragrance marketer Tristar to acquire portions of the company's mass market fragrance portfolio
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”